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Abstract
Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for novel 
therapeutic strategies in cancer. Here we show that acute inhibition of EGFR-driven glucose 
metabolism induces minimal cell death, yet lowers the apoptotic threshold in a subset of patient-
derived glioblastoma (GBM) cells. Mechanistic studies revealed that, following attenuated glucose 
consumption, Bcl-xL blocks cytoplasmic p53 from triggering intrinsic apoptosis. Consequently, 
pharmacological stabilization of p53 with the brain-penetrant small molecule, Idasanutlin, in 
combination with targeting EGFR-driven glucose metabolism promoted synthetic lethality in 
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orthotopic xenograft models. Notably, neither inhibition of EGFR signaling, nor genetic analysis 
of EGFR, was sufficient to predict sensitivity to this new therapeutic combination. Conversely, 
rapid changes in 18F-fluorodeoxyglucose (18F-FDG) uptake using non-invasive positron emission 
tomography was an effective predictive biomarker of response in vivo. Together, these studies 
identify a critical link between oncogene signaling, glucose metabolism, and cytoplasmic p53, 
which could be exploited for combination therapy in GBM and potentially, other malignancies.
Introduction
Molecularly targeted therapies have revolutionized cancer treatment and paved the path for 
modern precision medicine. However, despite well-defined actionable genetic alterations1, 
targeted drugs have failed in glioblastoma (GBM) patients. This is in large part due to 
insufficient brain penetration of most targeted agents to levels necessary for tumor kill2; this 
insufficient abundance in the target tissue may induce the development of adaptive 
mechanisms that drive drug resistance3. While therapeutic combinations that target both the 
primary genetic lesion and the compensatory signaling pathway(s) that promote resistance 
are appealing, these combination therapy strategies have been hampered by toxicities, 
requiring subthreshold dosing of each drug4,5. Owing to the dismal prognosis for GBM 
patients, and the poor efficacy of conventional approaches, new therapeutic strategies are 
critically needed.
An alternative therapeutic approach—synthetic lethality—targets an oncogenic driver to 
modify an important functional property for tumorigenesis, rendering cells vulnerable to an 
orthogonal second hit6. This strategy may be particularly attractive when the oncogene-
regulated functional network(s) modulate tumor cell death pathways. In a notable example, 
oncogenic signaling drives glucose metabolism to suppress the intrinsic (or mitochondria-
dependent) apoptotic pathway and prevent cell death7,8. Consequently, inhibition of 
oncogenic drivers with targeted therapies can trigger the intrinsic apoptotic machinery as a 
direct consequence of attenuated glucose consumption7. The intertwined nature of these 
tumorigenic pathways may present therapeutic opportunities for rational combination 
treatments, but this has yet to be investigated.
Previous work demonstrated that the epidermal growth factor receptor (EGFR) – mutated 
and/or amplified in ∼60% of GBM patients 9 – regulates glucose metabolism10. Whether 
targeting EGFR-driven glucose utilization alters the dynamics of the intrinsic apoptotic 
machinery in cancer is unknown. Here we hypothesized that a deeper understanding of this 
relationship will reveal pharmacological vulnerabilities for enhanced tumor killing in GBM.
Results
EGFR inhibitor metabolic responders and non-responders
We first characterized the changes in glucose uptake induced by acute EGFR inhibition 
across 19 patient-derived GBM cell lines. The cells were cultured in supplemented serum-
free medium as gliomaspheres which, in contrast to serum-based culture conditions, 
preserve many of the molecular features of patient tumors11,12. Treatment with the EGFR 
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tyrosine kinase inhibitor erlotinib revealed a subset of GBMs whose radio-labeled glucose 
uptake (18F-FDG) was significantly attenuated, hereafter termed “metabolic responders” 
(Fig. 1a and Supplementary Fig. 1a). Silencing of EGFR using siRNA confirmed that the 
reduction in glucose uptake was not due to off-target effects of erlotinib (Supplementary Fig. 
1b, c). Reduced 18F-FDG uptake was associated with, as determined from a randomly 
selected cohort of metabolic responders, decreased lactate secretion, glucose consumption, 
and extracellular acidification rate (ECAR), yet glutamine levels remained unchanged (Fig. 
1b and Supplementary Fig. 1d-g). Suppressed glucose utilization also correlated with a 
decrease in RAS-MAPK and PI3K-AKT-mTOR signaling – each of which can regulate 
glucose metabolism in GBM and other cancers 10,13,14 (Supplementary Fig. 2a).
In contrast, no “non-responder” GBMs (Fig. 1a and Supplementary Fig. 1b, c), showed 
reduced glucose consumption, lactate secretion, or ECAR despite robust inhibition of EGFR 
activity (Fig. 1b and Supplementary Fig. 1d-g) (Supplementary Fig. 2b). Moreover, RAS-
MAPK and PI3K-AKT-mTOR signaling were unchanged in nearly all metabolic non-
responders (Supplementary Fig. 2b). Notably, while all metabolic responders had alterations 
in EGFR (mutation and/or amplification, polysomy), 6 GBM lines without a metabolic 
response also contained EGFR mutations and/or copy number gains (Supplementary Fig. 3a, 
b). Taken together, these data illustrate two key points. First, acute inhibition of EGFR 
rapidly attenuates glucose utilization in a subset of primary GBM cells, and second, genetic 
alterations in EGFR could not alone predict which GBMs have a metabolic response to 
EGFR inhibition.
Metabolic responders are primed for apoptosis
Perturbations in glucose metabolism can induce the expression of pro-apoptotic factors and 
promote intrinsic apoptosis15, leading us to posit that reduced glucose uptake in response to 
EGFR inhibition would stimulate the intrinsic apoptotic pathway. Indeed, acute erlotinib 
treatment enhanced the expression of the pro-apoptotic BH3-only proteins, BIM and PUMA, 
only in the metabolic responder cultures (Supplementary Fig. 4a). However, annexin V 
staining revealed that the metabolic responders had only modest (∼17% cells annexin V 
positive), albeit significantly higher, apoptosis compared with non-responders (∼3% cells 
annexin V positive), following 72 hours of erlotinib exposure (Fig. 1c).
The relatively low level of apoptosis in metabolic responder GBMs, despite pronounced 
induction of pro-apoptotic factors, led us to ask if perturbing glucose uptake with erlotinib 
simply “primes” GBM cells for apoptosis; thus increasing the propensity for apoptosis 
without inducing considerable cell death16. The induction of a primed apoptotic state, or a 
shift in the death threshold, can be measured by BH3 profiling; which, is conducted via 
exposing the mitochondria of drug-treated cells to synthetic pro-apoptotic BH3 peptides 
(e.g., BIM, BID, and/or PUMA) and then quantifying the changes in mitochondria potential 
– via cytochrome c release – to precisely determine the proximity of cells to intrinsic 
apoptosis17. Accordingly, we treated both metabolic responders and non-responders for 24 
hours and performed BH3 profiling using multiple BH3 peptides across various 
concentrations (Supplementary Fig. 4b). We observed heightened apoptotic priming - as 
determined by the change in cytochrome c release relative to vehicle - in the metabolic 
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responders with erlotinib treatment (Fig. 1d). Importantly, priming in the metabolic 
responders was significantly higher than priming in the non-responders (Fig. 1d), supporting 
the premise that attenuated glucose uptake with EGFR inhibition triggers apoptotic priming 
in GBM.
We reasoned that if reduced glucose uptake is required for apoptotic priming with targeting 
EGFR, rescuing glucose consumption should mitigate these effects. Given that EGFR 
inhibition can abrogate the expression/localization of glucose transporters 1 (GLUT1) and 3 
(GLUT3) (Supplemental Fig. 5a)10, we ectopically expressed both GLUT1 and GLUT3 in 
two metabolic responder GBMs (HK301 and GBM39) to sustain glucose flux under 
erlotinib treatment. Enforced expression of GLUT1 and GLUT3 (GLUT1/3) rescued 
erlotinib-mediated attenuation of glucose consumption and lactate secretion in both cell lines 
(Fig. 1e and Supplementary Fig. 5b - d) and, importantly, markedly suppressed apoptotic 
priming in response to EGFR inhibition (Fig. 1f). Collectively, these data demonstrate that 
erlotinib-mediated inhibition of glucose metabolism, although insufficient to induce 
meaningful cell death, lowers the apoptotic threshold potentially rendering GBM cells 
vulnerable to agents that exploit this primed state.
Cytoplasmic p53 is required for apoptotic priming
Next, we investigated the mechanism by which GBMs become primed for apoptosis after 
treatment with erlotinib. In cells that are primed, the anti-apoptotic Bcl-2 family proteins 
(e.g. Bcl-2, Bcl-xL, Mcl-1) are largely loaded with pro-apoptotic BH3 proteins (e.g., BIM, 
BID, PUMA, BAD, NOXA, HRK); consequently, cells are dependent on these interactions 
for survival16. The tumor suppressor protein, p53, upregulates expression of pro-apoptotic 
proteins that subsequently need to be sequestered by anti-apoptotic Bcl-2 proteins to prevent 
cell death18. To examine whether p53 is required for erlotinib-induced priming, we 
abrogated p53 expression in two metabolic responders (HK301 and HK336) using CRISPR-
Cas9 targeting TP53; the resulting cells are hereafter referred to as p53KO (Fig. 2a). While 
the change in glucose uptake with erlotinib was unaffected in p53KO cells (Supplementary 
Fig. 6a), BH3 profiling revealed p53KO nearly abolished erlotinib-induced apoptotic 
priming (Fig. 2b)
As transcription of p53 target genes has been shown to be enhanced under glucose 
limitation15,19,20, we tested whether p53-mediated transcription was induced by EGFR 
inhibition. However, erlotinib neither increased the expression of p53-regulated genes (e.g., 
p21, MDM2, PIG3, TIGAR) (Supplementary Fig. 6b), nor induced p53-luciferase reporter 
activity in HK301 metabolic responder cells (Supplementary Fig. 6c). These data indicate 
that while p53 is required for priming with EGFR inhibition, its transcriptional activity may 
not be necessary.
In addition to p53's well-described nuclear functions, p53 can localize in the cytoplasm 
where it can directly engage the intrinsic apoptotic machinery via interactions with pro-
apoptotic and/or anti-apoptotic Bcl-2 family members21,22. To evaluate whether cytoplasmic 
p53 is important for apoptotic priming with erlotinib, we stably introduced a p53 mutant 
with a defective nuclear localization signal (p53cyto)23 into HK301 and HK336 p53KO 
gliomaspheres. As expected, p53cyto was expressed (Fig. 2c and Supplemental Fig. 6d), 
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restricted to the cytoplasm (Fig. 2d and Supplemental Fig. 6e) and had no transcriptional 
activity (Fig. 2e and Supplemental Fig. 2f). Conversely, reconstitution of wild-type p53 
(p53wt) in HK301 and HK336 p53KO cells displayed similar localization as parental cells 
and rescued transcription of p53-regulated genes (Fig. 2c - e and Supplemental Fig. 6e - g). 
Stable introduction of p53cyto significantly restored priming with erlotinib in both HK301 
and HK336 p53KO cells to levels comparable to p53wt (Fig. 2f and Supplemental Fig. 6g), 
indicating that the cytoplasmic function of p53 is required for erlotinib-mediated priming. In 
support of this conclusion, introduction of a transcriptionally active (Fig. 2g), yet nuclear-
confined p53 mutant (p53NES) into HK301 p53KO cells failed to induce erlotinib-mediated 
apoptotic priming (Fig. 2g, h and Supplemental Fig. 6h). Finally, pharmacological inhibition 
of cytoplasmic p53 activity with pifithrin-μ (PFTμ)24 markedly reduced priming with 
erlotinib (Supplementary Fig. 6i). Collectively, these results show that cytoplasmic p53 
engages the intrinsic apoptotic machinery following treatment with erlotinib in GBM 
metabolic responder samples.
Prior work demonstrated that TP53 mutations detected in human tumors – specifically those 
in the DNA binding domain – have diminished cytoplasmic functions in addition to 
transactivation deficiencies22,25. Thus, we asked whether stable expression of two of these 
“hotspot” p53 mutants, R175H or R273H, in HK301 p53KO would have reduced EGFRi-
mediated apoptotic priming (Supplementary Fig. 6h). As expected, both mutants lacked 
transcriptional capabilities (Fig. 2g) and, consistent with reduced cytoplasmic activity, were 
incapable of priming with erlotinib (Fig. 2h). Therefore, in line with previous findings, 
oncogenic mutations in the DNA binding domain of p53 result in “dual hits”26, whereby 
both transactivation and cytoplasmic functions are abrogated – the latter having implications 
for apoptotic priming with EGFR inhibition.
Inhibition of glucose uptake creates therapeutic vulnerability
Bcl-xL can sequester cytoplasmic p53 and prevent p53-mediated apoptosis; thus creating a 
primed apoptotic state and a dependency on Bcl-xL for survival27. Indeed, BH3 profiling 
revealed a reliance on Bcl-xL to block apoptosis in erlotinib metabolic responders 
(Supplementary Fig. 7a). Therefore, we hypothesized that attenuated glucose consumption 
with EGFR inhibition may result in the sequestration of cytoplasmic p53 by Bcl-xL. To 
investigate this, we performed co-immunoprecipitations to examine the dynamics of p53-
Bcl-xL interactions in response to erlotinib in both responders (n=2) and non-responders 
(n=2). Importantly, we observed increased Bcl-xL and p53 complex formation with erlotinib 
treatment in metabolic responders (Fig. 3a) but not in non-responders (Fig. 3b). This 
suggests that inhibition of EGFR-dependent glucose consumption results in sequestration of 
p53 by Bcl-xL. Consistent with this interpretation, ectopic expression of GLUT1/3, which 
rescues the erlotinib-mediated reduction in glucose uptake and apoptotic priming, prevented 
the association of p53 with Bcl-xL (Fig. 3c and Supplementary Fig. 7b). These findings 
strongly indicate that erlotinib-mediated inhibition of glucose uptake primes GBM cells for 
apoptosis by promoting an interaction between cytoplasmic p53 and Bcl-xL.
Disruption of the p53 and Bcl-xL complex can “free” cytoplasmic p53 to stimulate intrinsic 
apoptosis27. Once we detected increased binding between Bcl-xL and p53 in metabolic 
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responders in response to erlotinib, we asked whether the liberation of p53 from Bcl-xL 
elicits apoptosis. To test this, we treated a metabolic responder (HK301) with erlotinib and 
the specific Bcl-xL inhibitor, WEHI-53928. The addition of WEHI-539 released p53 from 
Bcl-xL under erlotinib treatment (Fig. 3d), leading to synthetic lethality in three metabolic 
responders (HK301, GBM39, HK336) (Fig. 3e and Supplementary Fig. 7c). Notably, 
cytoplasmic p53 was sufficient for caspase-dependent apoptosis elicited by the drug 
combination (Supplementary Fig. 7c, e). However, WEHI-539 did not enhance apoptosis in 
a non-responder (HK393) treated with erlotinib, suggesting that attenuation of glucose 
uptake with EGFR inhibition, and subsequent association between p53 and Bcl-xL, is 
necessary to lower the apoptotic threshold and generate a dependence on Bcl-xL for survival 
(Fig. 3e). In support of this, enforced expression of GLUT1/3 significantly mitigated cell 
death with the drug combination (Fig. 3f and Supplementary Fig. 7d). Together, these 
observations indicate that Bcl-xL blocks GBM cell death in response to erlotinib-mediated 
inhibition of glucose metabolism by sequestering cytoplasmic p53 (Fig. 3g).
Combination treatment efficacy in metabolic responders
Our mechanistic studies reveal a potential therapeutic opportunity in EGFR-driven GBMs 
that will be dependent on functional p53. While the p53 signaling axis is one of the three 
core pathways altered in GBM1,29, analysis of the TCGA GBM dataset demonstrated that 
TP53 mutations are mutually exclusive with alterations in EGFR (Fig. 4a, b). Conversely, in 
most patients with EGFR mutations or gains, there are co-occurring alterations that can lead 
to suppressed p53 activity; this includes amplification of MDM2 and/or deletions in the 
negative regulator of MDM2, p14 ARF, at the CDKN2A locus 30,31 (Fig. 4a, b). Given these 
relationships, and the requirement of p53 for priming under erlotinib-attenuated glucose 
uptake, we hypothesized that stabilization of p53 via MDM2 inhibition may have similar 
therapeutic effects to Bcl-xL antagonism. Using nutlin – an extensively characterized 
inhibitor of MDM232 – we noted synthetic lethality when paired with erlotinib in a 
metabolic responder gliomasphere. Greater than 90% of HK301 cells underwent apoptosis 
with combined erlotinib and nutlin (Fig. 4c). In contrast, we observed no synergy between 
these drugs in a metabolic non-responder (HK393, Fig. 4c). We then tested this combination 
across our panel of primary GBM cells (all p53 wild-type) and found synthetic lethality only 
in GBMs with a metabolic response to erlotinib, albeit less so in HK423 and HK296 
metabolic responders (Fig. 4d and Supplementary Fig. 8a)33. Silencing of EGFR in 
combination with nutlin also showed selective synergy for metabolic responder cells, 
suggesting that the effects of the drug combination were not due to any off-target effects of 
erlotinib (Supplemental Fig. 8b). Importantly, enforced expression of GLUT1/3 significantly 
reduced molecular markers of intrinsic apoptosis – including BAX oligomerization, and 
cytochrome c release - as well as cell death with combined erlotinib and nutlin (Fig. 4e and 
Supplementary Fig. 8c), supporting the concept that attenuated glucose metabolism with 
EGFR inhibition is required for the synthetic lethality of the drug combination.
We next investigated the role of p53 in eliciting cell death to combined erlotinib and nutlin. 
As expected, p53KO in two erlotinib metabolic responders (HK301 and HK336) abolished 
sensitivity to the drug combination (Fig. 4f and Supplementary Fig. 8g). Likewise, ectopic 
expression of Bcl-xL markedly suppressed cell death with combined treatment, consistent 
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with a critical function for Bcl-xL in antagonizing p53-mediated apoptosis (Supplementary 
Fig. 8d). Moreover, similar to our results with Bcl-xL inhibition (e.g., WEHI-539), the 
addition of nutlin liberated p53 from Bcl-xL under erlotinib treatment (Fig. 4g). These data 
are in agreement with prior observations that p53 stabilization can stimulate cytoplasmic 
p53-mediated apoptosis27,34. In support of the suggestion that cytoplasmic p53 activity is 
required for the synergy of erlotinib and nutlin in metabolic responders, blocking 
cytoplasmic p53 activity with PFTμ significantly mitigated apoptosis elicited with the 
combination (Supplementary Fig. 8e), while HK301 cells containing the nuclear-confined 
p53 mutant, p53NES, were incapable of enhanced cell death with the drug combination 
(Supplementary Fig. 8f). Finally, cells expressing the cancer “hotspot” p53 mutants, R175H 
and R273H, which have both transactivation and cytoplasmic deficiencies, were completely 
insensitive to the erlotinib and nutlin combination (Supplementary Fig. 8f).
It is noteworthy that while cytoplasmic p53 is absolutely required to promote cell death with 
combined erlotinib and nutlin, we observed in some instances that both the transcription-
dependent (i.e. nuclear) and independent functions of p53 (i.e. cytoplasmic) are needed for 
optimal execution of synergistic apoptosis with nutlin (Supplementary Fig. 8g). These 
results are consistent with reports that the cytoplasmic functions of p53 can alone execute 
intrinsic apoptosis34,35, whereas, in other contexts, may also require its nuclear functions to 
facilitate cytoplasmic p53 mediated cell kill27. Collectively, our results show that combined 
targeting of EGFR-driven glucose metabolism and p53 can induce marked synthetic lethality 
in primary GBM; which is dependent on the cytoplasmic functions of p53.
Priming metabolic non-responders for apoptosis
Our data has led us to propose a model where inhibition of EGFR-driven glucose 
metabolism primes the apoptotic machinery, resulting in synergy with pro-apoptotic stimuli 
such as p53 activation. A logical prediction of this model is that direct targeting of glucose 
metabolism should phenocopy the effects of EGFR inhibition. Consistent with this, addition 
of the glucose metabolic inhibitor 2-deoxyglucose (2DG) stimulated apoptotic priming, 
binding of p53 to Bcl-xL, and synthetic lethality with nutlin in HK301 metabolic responder 
cells. (Supplementary Fig. 9a, b, d). In contrast, inhibition of oxidative phosphorylation with 
oligomycin (complex V/ATP synthase) or rotenone (complex I) did not synergize with nutlin 
treatment in HK301 gliomaspheres (Supplementary Fig. 9c, d). Thus, reduced glucose 
metabolic flux alone, but not oxidative metabolism, appears to be sufficient for synergistic 
sensitivity to p53 activation.
This prompted us to consider whether modulating glucose consumption in non-responders 
results in a similar p53-dependent vulnerability. To investigate this, we tested whether direct 
inhibition of glucose uptake, with 2DG, or through targeting PI3K – a well characterized 
driver of glucose metabolism36 - elicits apoptotic priming in two erlotinib metabolic non-
responders (Fig. 5a). In contrast to erlotinib treatment, acute inhibition of PI3K with 
pictilisib abrogated PI3K-AKT-mTOR signaling (Supplementary Fig. 9e), and significantly 
reduced 18F-FDG uptake in HK393 and HK254 cells (Fig. 5b). The decrease in glucose 
consumption with pictilisib was associated with significantly higher apoptotic priming; 2DG 
treatment induced similar effects (Fig. 5b, c). Therefore, erlotinib metabolic non-responders 
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can be primed for apoptosis following inhibition of glucose uptake. Importantly, CRISPR/
CAS-9 targeting of p53 in HK393 cells significantly suppressed priming mediated by 2DG 
or pictilisib. (Fig. 5d). Moreover, p53-dependent priming was associated with heightened 
Bcl-xL and p53 binding, indicative of sequestration of p53 by Bcl-xL to block apoptosis 
(Fig. 5e and Supplementary Fig. 9f). In agreement with this interpretation, combining 2DG 
or pictilisib with nutlin caused significant, p53-dependent synthetic lethality in erlotinib 
non-responder cells (Fig. 5f, g). Taken together, these data demonstrate that acute inhibition 
of glucose metabolism, either directly or with targeted therapy, promotes p53-dependent 
apoptotic priming in GBM which creates a targetable vulnerability.
A non-invasive biomarker for combination treatment in vivo
Our results in cell culture show that combined targeting of oncogene-driven glucose 
metabolism and p53 has synergistic activity in primary GBM. This led us to investigate 
whether this approach could be effective in orthotopic GBM xenograft models. For these 
studies, we used the MDM2 inhibitor, Idasanutlin, which is currently in clinical trials for 
many malignancies37. Given the uncertainty of CNS penetration of Idasanutlin, we first 
demonstrated that Idasanutlin can accumulate in the brains of mice with a completely intact 
blood-brain-barrier (∼35% relative to plasma levels) and stabilizes p53 in orthotopic tumor-
bearing mice (Supplementary Fig. 10a, b).
Next, as perturbations in glucose metabolism with oncogene inhibition are required for 
synergistic sensitivity to p53 activation, we hypothesized that rapid attenuation in glucose 
uptake in vivo following erlotinib administration – as measured by 18F-FDG PET – could 
serve as a non-invasive predictive biomarker for therapeutic efficacy of combined erlotinib 
and Idasanutlin treatment (Fig. 6a). We observed, in orthotopic xenografts of a metabolic 
responder gliomasphere (GBM39), that acute erlotinib treatment (75 mg/kg) rapidly 
reduced 18F-FDG uptake (15 hours post erlotinib administration, see Materials and 
Methods) (Fig. 6b and Supplementary Fig. 10c). In separate groups of mice, we tested the 
individual drugs and the combination of daily erlotinib (75 mg/kg) and Idasanutlin (50 
mg/kg) treatment for up to 25 days. The drug combination was tolerable over the treatment 
period; we noted a ∼10% decrease in body weight, which was comparable to erlotinib 
treatment alone (Supplementary Fig. 10d). Relative to single agent controls, combined 
erlotinib and Idasanutlin demonstrated synergistic growth inhibition – as determined by 
secreted gaussia luciferase38 - in GBM39 intracranial tumor-bearing mice (Fig. 6c and). In 
contrast, orthotopic xenografts of a non-metabolic responder (HK393) showed no changes 
in 18F-FDG uptake with acute erlotinib (Fig. 6d and Supplementary Fig. 10c), nor 
synergistic activity with the erlotinib and Idasanutlin combination (Fig. 6e). Thus, non-
invasive 18F-FDG PET, used to measure rapid changes in glucose uptake with EGFR 
inhibition, was effective in predicting subsequent synergistic sensitivity to combined 
erlotinib and Idasanutlin
Finally, we evaluated the effects of the drug combination on overall survival in orthotopic 
xenografts of either two erlotinib metabolic responders (GBM39 and HK336) or two non-
responders (HK393 and GS025). All tumors were p53 wild-type (Supplemental Fig. 3a). 
Following evidence of tumor growth (as determined by gaussia luciferase), mice were 
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treated with vehicle, erlotinib, Idasanutlin, or the combination for up to 25 days and then 
release of therapy; the short-term treatment due to limited quantities of Idasanutlin for these 
studies. Despite all tumors having genetic alterations in EGFR (e.g., mutation and/or 
amplification, polysomy), the drug combination led to a pronounced increase in survival 
only in animals bearing erlotinib metabolic responder GBM tumors (Fig. 6f-i). Taken 
together, these data show that combined targeting of EGFR and p53 synergistically inhibits 
growth and prolongs survival in a subset of p53 wild-type GBM orthotopic xenografts, and 
that 18F-FDG PET is a non-invasive predictive biomarker of sensitivity to this new 
combination therapeutic strategy.
Discussion
Here we found that acute EGFR inhibition rapidly reduces glucose utilization in a subset of 
patient-derived GBMs. As a consequence to this altered metabolic state, unexpectedly, cells 
become primed for apoptosis via the cytoplasmic functions of p53. Accordingly, 
pharmacological p53 stabilization – with a novel brain-penetrant small molecule - was 
synthetically lethal with inhibition of EGFR-driven glucose uptake in primary orthotopic 
GBM models. While these preclinical systems do not fully recapitulate the features of 
human GBM - consisting of an active immune system, pseudopalisading necrosis, and 
microvasculature proliferation - our results provide a proof of concept that deploying 
targeted agents to perturb and exploit altered tumor metabolism could be an effective 
therapeutic strategy in GBM.
The majority of studies suggest that the apoptotic functions of p53 are primarily exerted 
through its transcriptional activity. However, recent work supports the suggestion that the 
non-transcriptional functions of p53 can have a critical role in triggering intrinsic 
apoptosis26. Our results provide, to the best of our knowledge, the first demonstration that 
cytoplasmic p53 couples oncogenic signaling to intrinsic apoptosis; which in this case is 
dependent on alterations in glucose utilization. However, it is remains unknown the 
metabolic pathway(s) downstream of glucose uptake that is responsible for this effect. The 
observation that direct inhibition of oxidative phosphorylation does not synergize with p53 
activation suggests that oxidation of glucose or other metabolites (e.g., glutamine) is not 
required (Supplementary Fig. 9c, d). Glucose can feed into many metabolic pathways 
including those for anabolic processes (e.g., lipids, nucleotides, amino acids), energetics, and 
enzyme function (e.g., glycosylation, acetylation). Thus, attenuated glucose consumption 
may affect multiple pathways to induce sufficient metabolic stress39 and/or reduced donor 
metabolic substrates40,41 to stimulate the cytoplasmic functions of p53. Future studies are 
required to specifically define these metabolic nodes that render GBM cells exquisitely 
susceptible to cytoplasmic p53-mediated apoptosis. This could reveal analogous therapeutic 
vulnerabilities to exploit GBM tumors for p53-dependent cell death.
More work is also needed to understand precisely how cytoplasmic p53 triggers intrinsic 
apoptosis in GBM cells. Considerable evidence indicates that cytoplasmic p53 possesses 
similar functionality as pro-apoptotic BH3 proteins, where it can activate the pro-apoptotic 
effectors BAK22,42 or BAX directly21 and/or indirectly via neutralizing anti-apoptotic Bcl2 
proteins22. Our results support this role for cytoplasmic p53 whereby, following attenuated 
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glucose metabolism, p53 engages the intrinsic apoptotic machinery via binding to the anti-
apoptotic protein Bcl-xL. Despite minimal cell death, the increased occupancy of Bcl-xL 
with p53 lowers the apoptotic threshold and creates a dependency on Bcl-xL to block p53-
mediated cell death. Targeting this interaction (e.g., BCL-xL inhibition or MDM2 
antagonism) liberated p53 from Bcl-xL which coincided with BAX activation and 
cytoplasmic p53-dependent intrinsic apoptosis. This raises the possibility that “free” 
cytoplasmic p53 is directly activating BAX to promote apoptosis in response to this 
therapeutic combination. Finally, it is important to note that while cytoplasmic p53 was 
necessary for the execution of synergistic apoptosis with either Bcl-xL or MDM2 inhibition, 
it was universally sufficient only in the context of Bcl-xL inhibition (Supplemental Fig. 7c 
and Supplemental Fig. 8g). This apparent discrepancy may be explained through 
observations that, in some instances, the displacement of cytoplasmic p53 from Bcl-xL 
requires the binding of the p53 transcriptional target gene PUMA27,43. As MDM2 
antagonists can stimulate nuclear p53 transcriptional activity, including expression of 
PUMA, it possible that in some contexts the transcription-dependent functions of p53 are 
required to facilitate cytoplasmic p53-mediated apoptosis in GBM.
It is noteworthy that neither genetic alterations in EGFR nor inhibition of EGFR activity 
were sufficient to predict a metabolic response with EGFR TKI in our GBM samples. 
Several molecular mechanisms have been described that can enable dynamic compensatory 
responses to EGFR-directed therapy in GBM44. Thus, it is likely that, despite robust 
inhibition of EGFR, some tumors quickly rewire their molecular circuitry to preserve 
downstream signaling flux and drive glucose consumption45. Given the breadth of potential 
adaptive mechanisms, coupled with the molecular heterogeneity of GBM, genetic 
biomarkers may alone be insufficient to predict responses to this approach. Our results 
emphasize the value of a functional biomarker, in this case changes in glucose uptake46, as a 
means to rapidly stratify metabolic responders and non-responders.
Taken together, our findings provide rationale for the clinical evaluation of combined 
targeting of oncogene-driven glucose metabolism (e.g., EGFRi or PI3Ki) and p53 in GBM 
patients. Furthermore, we propose a new clinical application of 18F-FDG PET to assess 
whether targeted drugs have induced a metabolic vulnerability that can be exploited. As we 
show that changes in 18F-FDG accumulation can be observed within hours of EGFR 
inhibitor treatment, 18F-FDG PET could serve as a rapid, non-invasive functional biomarker 
to predict synergistic sensitivity to p53 activation. This non-invasive analysis could be 
particularly valuable for malignant brain tumors, where pharmacokinetic/pharmacodynamic 
assessment is extremely difficult and impractical. While there are concerns that 18F-FDG 
PET cannot properly delineate tumor glucose uptake versus healthy brain tissue glucose 
uptake, delayed imaging protocols47 (used here for the mouse studies) and parametric 
response maps (PRMs) with MRI fusion can be useful for quantifying the changes in 
tumor 18F-FDG consumption. Lastly, targeting oncogenes that drive glucose uptake in other 
cancers may evoke similar p53-dependent vulnerabilities. Future work is required to assess 
the applicability of this concept to other oncogenic drivers and cancers.
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Online Methods
Mice
Female NOD scid gamma (NSG), 6-8 weeks of age, were purchased from the University of 
California Los Angeles (UCLA) medical center animal breeding facility. Male CD-1 mice, 
6-8 weeks of age, were purchased from Charles River. All mice were kept under defined 
flora pathogen-free conditions at the AAALAC-approved animal facility of the Division of 
Laboratory Animals (DLAM) at UCLA. All animal experiments were performed with the 
approval of the UCLA Office of Animal Resource Oversight (OARO).
Patient-derived GBM cells
All patient tissue to derive GBM cell cultures was obtained through explicit informed 
consent, using the UCLA Institutional Review Board (IRB) protocol: 10-000655. As 
previously described12, primary GBM cells were established and maintained in 
gliomasphere conditions consisting of DMEM/F12 (Gibco), B27 (Invitrogen), Penicillin-
Streptomycin (Invitrogen), and Glutamax (Invitrogen) supplemented with Heparin (5 μg/mL, 
Sigma), EGF (50 ng/mL, Sigma), and FGF (20 ng/mL, Sigma). All cells were grown at 
37°C, 20% O2, and 5% CO2 and were routinely monitored and tested negative for the 
presence of mycoplasma using a commercially available kit (MycoAlert, Lonza). At the time 
of experiments, most HK lines used were between 20-30 passages (exceptions HK385 p8, 
HK336 p15), while GS and GBM39 lines were less than 10 passages. All cells were 
authenticated by short-tandem repeat (STR) analysis.
Reagents and antibodies
Chemical inhibitors from the following sources were dissolved in DMSO for in vitro 
studies: Erlotinib (Chemietek), Nutlin-3A (Selleck Chemicals), WEHI-539 (APExBIO), 
Pictilisib (Selleck Chemicals), Oligomycin (Sigma), Rotenone (Sigma). 2DG (Sigma) was 
dissolved freshly in media prior to usage. Antibodies used for immunoblotting were 
obtained from the listed sources: β-actin (8H10D10) Mouse mAb (Cell signaling, 3700), 
tubulin (DM1A) Mouse mAb (Cell signaling, 3873), p-EGFR Y1086 (2533287) Rabbit pAb 
(Thermo Fischer Scientific, 36-9700), t-EGFR Rabbit pAb (Millipore, 06-847), t-AKT 
(11E7) Rabbit mAb (Cell Signaling, 4685), p-AKT T308 (D25E6) Rabbit mAb (Cell 
Signaling, 13038), p-AKT S473 (D9E) Rabbit mAb (Cell Signaling, 4060), t-ERK (137F5) 
Rabbit mAb (Cell Signaling, 4695), p-ERK T202/Y204 (D13.14.4E) Rabbit mAb (Cell 
Signaling, 4370), t-S6 (5G10) Rabbit mAb (Cell Signaling, 2217), p-S6 S235/236 
(D57.2.2E) Rabbit mAb (Cell Signaling, 4858), t-4EBP1 (53H11) Rabbit mAb (Cell 
Signaling, 9644), p-4EBP1 S65 Rabbit pAb (Cell Signaling 9451), Glut3 Rabbit pAb 
(Abcam, ab15311), Glut1 Rabbit pAb (Millipore, 07-1401), p53 (DO-1) Mouse mAb (Santa 
Cruz Biotechnology, SC-126), BAX (D2E11) Rabbit mAb (Cell Signaling, 5023), BIM 
(C34C5) Rabbit mAb (Cell Signaling, 2933), PUMA (D30C10) Rabbit mAb (Cell 
Signaling, 12450), Bcl-2 (50E3) Rabbit mAb (Cell Signaling, 2870), Bcl-xL (54H6) Rabbit 
mAb (Cell Signaling, 2764), Mcl-1 (D35A5) Rabbit mAb (Cell Signaling, 5453), 
Cytochrome c Rabbit pAb (Cell Signaling, 4272), and Cleaved Caspase-3 Rabbit pAb (Cell 
Signaling, 9661). Antibodies used for immunoprecipitation were obtained from the listed 
sources: p53 Rabbit pAb (Cell Signaling, 9282). Secondary antibodies were obtained from 
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the listed sources: Anti-rabbit IgG HRP-linked (Cell Signaling, 7074) and Anti-mouse IgG 
HRP-linked (Cell Signaling, 7076). All immunoblotting antibodies were used at a dilution of 
1:1000, except β-actin and tubulin, which were used at 1:10,000. Immunoprecipitation 
antibodies were diluted according to manufacturer's instructions (1:200 for p53). Secondary 
antibodies were used at a dilution of 1:5000.
18F-Fluorodeoxyglucose (18F-FDG) uptake assay
Cells were plated at 5 × 104 cells/ml and treated with designated drugs for indicated time 
points. Following appropriate treatment, cells were collected and resuspended in glucose-
free DMEM/F12 (US Biological) containing 18F-FDG (radioactivity 1 μCi/mL). Cells were 
incubated at 37°C for 1 hr and then washed three times with ice cold PBS. Radioactivity of 
each sample was then measured using a gamma counter.
Glucose, glutamine, and lactate measurements
Cellular glucose consumption and lactate production were measured using a Nova 
Biomedical BioProfile Basic Analyzer. Briefly, cells were plated in 1 × 105 cells/ml in 2 mL 
of gliomasphere conditions and appropriate drug conditions. 12 hrs following drug 
treatment, 1 ml of media was removed from each sample and analyzed in the Nova 
BioProfile analyzer. Measurements were normalized to cell number.
Annexin V apoptosis assay
Cells were collected and analyzed for Annexin V and PI staining according to 
manufacturer's protocol (BD Biosciences). Briefly, cells were plated at 5 × 104 cells/ml and 
treated with appropriate drugs. Following indicated time points, cells were collected, 
trypsinized, washed with PBS, and stained with Annexin V and PI for 15 minutes. Samples 
were then analyzed using the BD LSRII flow cytometer.
Immunoblotting
Cells were collected and lysed in RIPA buffer (Boston BioProducts) containing Halt 
Protease and Phosphatase Inhibitor (Thermo Fischer Scientific). Lysates were centrifuged at 
14,000×g for 15min at 4°C. Protein samples were then boiled in NuPAGE LDS Sample 
Buffer (Invitrogen) and NuPAGE Sample Reducing Agent (Invitrogen) and separated using 
SDS-PAGE on 12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membrane 
(GE Healthcare). Immunoblotting was performed per antibody's manufacturer's 
specifications and as mentioned previously. Membranes were developed using the 
SuperSignal system (Thermo Fischer Scientific).
Immunoprecipitation
Cells were collected, washed once with PBS, and incubated in IP lysis buffer (25 mM Tris-
HCL pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% Glycerol) at 4°C for 15 minutes. 
300-500 μg of each sample was then pre-cleared in Protein A/G Plus Agarose Beads 
(Thermo Fischer Scientific) for one hour. Following pre-clear, samples were then incubated 
with antibody-bead conjugates overnight according to manufacturer's specifications and as 
mentioned previously. The samples were then centrifuged at 1000g for 1 min, and the beads 
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were washed with 500 μL of IP lysis buffer for five times. Proteins were eluted from the 
beads by boiling in 2× LDS Sample Buffer (Invitrogen) at 95°C for 5 min. Samples analyzed 
by immunoblotting as previously described. Immunoprecipitation antibodies were diluted 
according to manufacturer's instructions (1:200 for p53 and 1:100 for Bcl-xL).
Dynamic BH3 profiling
GBM gliomaspheres were first disassociated to single-cell suspensions with TrypLE (Gibco) 
and resuspended in MEB buffer (150 mM Mannitol 10 mM HEPES-KOH, 50 mM KCl, 0.02 
mM EGTA, 0.02 mM EDTA, 0.1 % BSA, 5 mM Succinate). 50μl of cell suspension (3 × 104 
cells/well) were plated in wells holding 50 μL MEB buffer containing 0.002% digitonin and 
indicated peptides in 96-well plates. Plates were then incubated at 25°C for 50 min. Cells 
were then fixed with 4% paraformaldehyde for 10min, followed by neutralization with N2 
buffer (1.7M Tris, 1.25M Glycine pH 9.1) for 5min. Samples were stained overnight with 20 
μL of staining solution (10% BSA, 2% Tween 20 in PBS) containing DAPI and anti-
cytochrome c (BioLegend). The following day, cytochrome c release was quantified using 
BD LSRII flow cytometer. Measurements were normalized to appropriate controls that do 
not promote cytochrome c release (DMSO and inactive PUMA2A peptide). Delta priming 
refers to the difference in amount of cytochrome c release between vehicle treated cells and 
drug treated cells.
Plasma membrane protein extraction
1 × 107 cells were treated with indicated drugs. Following 4hr of treatment, cells were 
collected, washed once with ice cold PBS, and lysed using a Dounce Homogenizer. Plasma 
membrane protein extraction proceeded following manufacturer's protocol (BioVision), and 
isolated proteins were then subject to immunoblotting.
BAX oligomerization
7.5 × 105 cells were treated with indicated drugs. Following 24 hr of treatment, cells were 
collected, washed once with ice cold PBS, and re-suspended in 1 mM bismaleimidohexane 
(BMH) in PBS for 30 min. Cells were then pelleted and lysed for immunoblotting, as 
described above.
Cytochrome c detection
5 million cells were plated at a concentration of 1×105 cells/mL and treated with indicated 
drugs. Following 24 hr of treatment, cells were collected, washed once with ice cold PBS. 
Subcellular fractionation was then performed using a mitochondrial isolation kit (Thermo 
Fischer Scientific, 89874). Both cytoplasmic and mitochondrial fractions were subjected to 
immunoblotting and cytochrome c was detected using cytochrome c antibody at a dilution of 
1:1000 (Cell Signaling, 4272).
Mouse xenograft studies
For intracranial experiments, GBM39, HK336, HK393, and GS025 cells were injected (4 × 
105 cells per injection) into the right striatum of the brain of female NSG mice (6-8 weeks 
old). Injection coordinates were 2 mm lateral and 1 mm posterior to bregma, at a depth of 2 
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mm. Tumor burden was monitored by secreted gaussia luciferase and following three 
consecutive growth measurements, mice were randomized into four treatment arms 
consisting of appropriate vehicles, 75 mg/kg erlotinib, 50 mg/kg Idasanutlin, or a 
combination of both drugs. Vehicle consisted of 0.5% methylcellulose in water, which is 
used to dissolve erlotinib, and a proprietary formulation obtained from Roche, which is used 
to dissolve Idasanutlin. Tumor burden was assessed twice per week by secreted gaussia 
luciferase. When possible, mice were treated for 25 days and taken off treatment and 
monitored for survival. Drugs were administered through oral gavage. Sample sizes were 
chosen based off estimates from pilot experiments and results from previous literature12. 
Investigators were not blinded to group allocation or assessment of outcome. All studies 
were in accordance with UCLA OARO protocol guidelines.
Intracranial delayed PET/CT mouse imaging
For baseline 18F-FDG scans, mice were treated with vehicle and 15 hours later were pre-
warmed, anesthetized with 2% isoflurane, and intravenously injected with 70 μCi of 18F-
FDG. Following 1hr unconscious uptake, mice were taken off anesthesia but kept warm for 
another 5 hr of uptake. 6 hr after the initial administration of 18F-FDG, mice were imaged 
using G8 PET/CT scanner (Sofie Biosciences). Following imaging, all mice were then dosed 
with erlotinib (75 mg/kg) and 15 hours later went through the same imaging procedure. Per 
above, quantification was performed by drawing 3D regions of interest (ROI) using the 
AMIDE software as previously described48. Note, the 15 hour treatment time point was the 
earliest time point that fit within the logistical constraints; this includes half-lives required 
for adequate probe decay for subsequent imaging, 18F-FDG production schedule and 
imaging center hours.
Immunohistochemistry
Immunohistochemistry was performed on 4 μm sections that were cut from FFPE (formalin-
fixed, paraffin-embedded) blocks. Sections were then deparaffinised with xylene and 
rehydrated through graded ethanol. Antigen retrieval was achieved with a pH 9.5 Nuclear 
Decloaker (Biocare Medical) in a Decloaking pressure cooker at 95°C for 40 min. Tissue 
sections were then treated with 3% hydrogen peroxide (LOT 161509; Fisher Chemical) and 
with Background Sniper (Biocare Medical, Concord, CA, USA) to reduce nonspecific 
background staining. Primary antibody for p53 (Cell Signaling, 2527) was applied in a 1:150 
dilution for 80 min followed by detection with the MACH 3 Rabbit HRP- Polymer 
Detection kit (Biocare Medical). Visualization was achieved using VECTOR NovaRED 
(SK-4800; Vector Laboratories, Inc.) as chromogen. Lastly, sections were counterstained 
with Tacha's Automated Hematoxylin (Biocare Medical).
Quantitative RT-PCR
RNA was extracted from all cells using Purelink RNA Kit (Invitrogen). cDNA was 
synthesized with iScript cDNA Synthesis Kit (Bio-Rad) as per manufacturer's instructions. 
Quantitative PCR (qPCR) was conducted on the Roche LightCycler 480 using SYBRGreen 
Master Mix (Kapa Biosciences). Relative expression values are normalized to control gene 
(GAPDH). Primer sequences are as listed (5′ to 3′): P21 (forward 
GACTTTGTCACCGAGACACC, reverse GACAGGTCCACATGGTCTTC), PUMA 
Mai et al. Page 14
Nat Med. Author manuscript; available in PMC 2018 April 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(forward ACGACCTCAACGCACAGTACG, reverse 
GTAAGGGCAGGAGTCCCATGATG), GAPDH (forward 
TGCCATGTAGACCCCTTGAAG, reverse ATGGTACATGACAAGGTGCGG), MDM2 
(forward CTGTGTTCAGTGGCGATTGG, reverse AGGGTCTCTTGTTCCGAAGC), 
TIGAR (forward GGAAGAGTGCCCTGTGTTTAC, reverse 
GACTCAAGACTTCGGGAAAGG), PIG3 (forward GCAGCTGCTGGATTCAATTA, 
reverse TCCCAGTAGGATCCGCCTAT)
P53 reporter activity
Cells were first infected with lentivirus synthesized from a p53 reporter plasmid which codes 
for luciferase under the control of a p53 responsive element: 
TACAGAACATGTCTAAGCATGCTGTGCCTTGCCTGGACTTGCCTGGCCTTGCCTTG
GG. Infected cells were then plated into a 96-well plate at 5,000 cells/ 50 μL and treated 
with indicated drugs for 24 hr and then incubated with 1 mM D-luciferin for two hours. 
Bioluminescence was measured using IVIS Lumina II (Perkin Elmer).
Genetic manipulation
In general, lentivirus used for genetic manipulation were produced by transfecting 293-FT 
cells (Thermo) using Lipofectamine 2000 (Invitrogen). Virus was collected 48 hours after 
transfection. The lentiviral sgp53 vector and sgControl vector contained the following guide 
RNA, respectively: CCGGTTCATGCCGCCCATGC and GTAATCCTAGCACTTTTAGG. 
LentiCRISPR-v2 was used as the backbone. Glut1 and Glut3 cDNA was cloned from 
commercially available vectors and incorporated into pLenti-GLuc-IRES-EGFP lentiviral 
backbone containing a CMV promoter (Glut1 was a gift from Wolf Frommer (Addgene 
#1808549), Glut3 was obtained from OriGene #SC115791, and the lentiviral backbone was 
obtained from Targeting Systems #GL-GFP). pMIG Bcl-xL was a gift from Stanley 
Korsmeyer (Addgene #879050) and cloned into the lentiviral backbone mentioned above 
(Targeting Systems). Cytoplasmic (K305A and R306A) and wild-type p53 constructs were a 
kind gift from R. Agami and G. Lahav. The genes of interest were cloned into a lentiviral 
vector containing a PGK promoter. Constructs for p53 DNA binding domain mutants 
(R175H) and (R273H) as well as the nuclear mutant (L348A and L350A) were generated 
using site-directed mutagenesis (New England Biolabs #E0554S) on the wild-type p53 
construct.
For EGFR knockdown experiments, siRNA against EGFR (Thermo Fischer Scientific, s563) 
was transfected into cells using DharmaFECT 4 (Dharmacon). Following 48 hours, cells 
were harvested and used for indicated experiments.
Immunofluorescence
For immunofluorescence, gliomaspheres were first disassociated to single cell and adhered 
to the 96-well plates using Cell-Tak (Corning) according to manufacturer instructions. 
Adhered cells were then fixed with ice-cold methanol for 10 min then washed three times 
with PBS. Cells were then incubated with blocking solution containing 10% FBS and 3% 
BSA in PBS for 1 hr and subsequently incubated with p53 (Santa Cruz, SC-126, dilution of 
1:50) antibody overnight at 4°C. The following day, cells were incubated with secondary 
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antibody (Alexa Fluor 647, dilution 1:2000) for an hour and DAPI staining for 10 min, then 
imaged using a Nikon TI Eclipse microscope equipped with a Cascade II fluorescent camera 
(Roper Scientific). Cells were imaged with emissions at 461 nM and 647 nM and then 
processed using NIS-Elements AR analysis software.
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measurements
For metabolic measurements involving OCR and ECAR, gliomaspheres treated with 
indicated drugs were first disassociated to single-cell suspensions and adhered to XF24 
plates (Seahorse Bioscience) using Cell-Tak (Corning) according to manufacturer 
instructions. Prior to the assay, cells were supplemented with unbuffered DMEM, and 
incubated at 37°C for 30 min before starting OCR and ECAR measurements. Basal ECAR 
measurements between control and erlotinib treated cells are shown.
Mass-spectroscopy sample preparation
Male CD-1 mice (6-8 weeks old) were treated with 50 mg/kg Idasanutlin in duplicate 
through oral gavage. At 0.5, 1, 2, 4, 6, 8, 12, and 24 hr after administration, mice were 
sacrificed, blood was harvested by retro-orbital bleeding, and brain tissue was collected. 
Whole blood from mice was centrifuged to isolate plasma. Idasanutlin was isolated by 
liquid-liquid extraction from plasma: 50 μL plasma was added to 2 μL internal standard and 
100 μL acetonitrile. Mouse brain tissue was washed with 2 mL cold PBS and homogenized 
using a tissue homogenizer with fresh 2 mL cold PBS. Idasanutlin was then isolated and 
reconstituted in a similar manner by liquid-liquid extraction: 100 μL brain homogenate was 
added to 2 μL internal standard and 200 μL acetonitrile. After vortex mixing, the samples 
was centrifuged. The supernatant was removed and evaporated by a rotary evaporator and 
reconstituted in 100 μL 50:50 water: acetonitrile.
Idasanutlin detection by mass-spectrometry
Chromatographic separations were performed on a 100 × 2.1 mm Phenomenex Kinetex C18 
column (Kinetex) using the 1290 Infinity LC system (Agilent). The mobile phase was 
composed of solvent A: 0.1% formic acid in Milli-Q water, and B: 0.1% formic acid in 
acetonitrile. Analytes were eluted with a gradient of 5% B (0-4 min), 5-99% B (4-32 min), 
99% B (32-36 min), and then returned to 5% B for 12 min to re-equilibrate between 
injections. Injections of 20 μL into the chromatographic system were used with a solvent 
flow rate of 0.10 mL/min. Mass spectrometry was performed on the 6460 triple quadrupole 
LC/MS system (Agilent). Ionization was achieved by using electrospray in the positive 
mode and data acquisition was made in multiple reactions monitoring (MRM) mode. The 
MRM transition used for Idasanutlin detection was m/z 616.2 → 421.2 with fragmentor 
voltage of 114V, and collision energy of 20 eV. Analyte signal was normalized to the 
internal standard and concentrations were determined by comparison to the calibration curve 
(0.5, 5, 50, 250, 500, 2000 nM). Idasanutlin brain concentrations were adjusted by 1.4% of 
the mouse brain weight for the residual blood in the brain vasculature as described by Dai et 
al 51.
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Secreted gaussia luciferase measurements
Cells were infected with a lentiviral vector containing secreted gaussia luciferase (sGluc) 
reporter gene (Targeting Systems # GL-GFP) and intracranially implanted into the right 
striatum of mice (4 × 105 cells/mouse). To measure the levels of secreted Gaussia luciferase 
(sGluc), 6 μL of blood was collected from the tail vein of the mice and immediately mixed 
with 50 mM EDTA to prevent coagulation. Gluc activity was obtained by measuring 
chemiluminescence following injection of 100 μL of 100 μM coelentarazine (Nanolight) in a 
96 well plate as described before.38
Synergy score calculations
1.0 × 105 GBM cells were plated in triplicate and treated with erlotinib, nutlin, or 
combination at multiple concentrations using a matrix where each drug was added to the 
cells at six concentrations (0-10 μM). Annexin V staining was measured following 72 hrs of 
treatment. Using the Chalice software, as described in Lehar et al., the response of the 
combination was compared to its single agents, and the combinatorial effects were 
calculated using the synergy score33.
DNA sequencing
Targeted sequencing was performed for samples HK206, HK217, HK250, HK296 for the 
following genes BCL11A, BCL11B, BRAF, CDKN2A, CHEK2, EGFR, ERBB2, IDH1, 
IDH2, MSH6, NF1, PIK3CA, PIK3R1, PTEN, RB1, TP53 using Illumina Miseq. There 
were 1 to 2 million reads per sample with average coverage of 230 per gene. Copy number 
variants were determined for these samples using a whole genome SNP array. The genetic 
profile of GBM39 has been previously reported45.
Whole exome sequencing was performed for samples HK157, HK229, HK248, HK250, 
HK254, HK296, HK301, HK336, HK350, HK390, HK393 and carried out at SeqWright. 
Samples were grouped into 2 pools with separate capture reactions. Nextera Rapid capture 
and library preparation were used and sequencing performed on a HiSeq 2500, 2×100 bp 
with 100× on-target coverage, 2 full rapid runs, each with 1 normal diploid control. Copy 
number analysis for these samples was carried out using EXCAVATOR software: http://
genomebiology.com/content/pdf/gb-2013-14-10-r120.pdf
Data-availability statement
Data presented in this manuscript are available from the corresponding authors upon request.
Annotation of TCGA samples
273 GBM samples from the TCGA were analyzed for genetic alterations in EGFR, p53 and 
p53-regulated pathways. Co-occurrences of mutations were examined and only significant 
interactions are displayed. Data was analyzed using cBioPortal as previously described 52,53.
Fluorescence in situ Hybridization (FISH)
Fluorescence in situ hybridization (FISH) was performed using commercially available 
fluorescently labeled dual-color EGFR (red)/CEP 7(green) probe (Abbott-Molecular). FISH 
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hybridization and analyses were performed on cell lines, following the manufacturer's 
suggested protocols. The cells were counterstained with DAPI and the fluorescent probe 
signals were imaged under a Zeiss (Axiophot) Fluorescent Microscope equipped with dual- 
and triple-color filters.
Statistical analysis
Comparisons were made using two-tailed unpaired Student's t-tests and p values <0.05 were 
considered statistically significant. All data from multiple independent experiments were 
assumed to be of normal variance. For each experiment, replicates are as noted in the figure 
legends. Data represent mean ± s.d. values unless otherwise indicated. All statistical 
analyses were calculated using Prism 7.0 (GraphPad). For all in vitro and in vivo 
experiments, no statistical method was used to predetermine sample size and no samples 
were excluded. For in vivo tumor measurements, the last data sets were used for 
comparisons between groups. As described above, all mice were randomized before studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Inhibition of EGFR-driven glucose metabolism induces minimal cell death but primes 
GBM cells for apoptosis
(a) Percent change in 18F-FDG uptake after 4 hours of 1 μM erlotinib treatment relative to 
vehicle in 19 patient-derived GBM gliomaspheres. Concentration of erlotinib was selected to 
achieve robust inhibition of EGFR activity across our panel of primary GBM cells (see 
Supplemental Fig. 2). “Metabolic responders” (blue) are samples that show a significant 
decrease in 18F-FDG uptake relative to vehicle, whereas “non-responders” (red) show no 
significant decrease (mean ± s.d., n ≥ 3). (b) % change in glucose consumption and lactate 
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secretion with 12 hours of 1 μM erlotinib treatment relative to vehicle. Measurements were 
made using Nova Biomedical BioProfile Analyzer (mean ± s.d., n ≥ 5). (c) Annexin V 
staining of metabolic responders (blue, n = 10 unique gliomaspheres) or non-responders 
(red, n = 9 unique gliomaspheres) after treatment with 1 μM erlotinib for 72 hours. Each 
point represents the mean apoptosis of two independent experiments conducted for each 
gliomasphere sample. See Supplementary Fig. 11 for flow cytometry gating strategy. (d) The 
% change, relative to vehicle control, in priming as determined by cytochrome c release 
following exposure to each BH3 peptide (BIM, BID, or PUMA) in metabolic responders or 
non-responders treated with 1 μM erlotinib for 24 hours (mean ± s.d., n = 2). Statistical 
analysis was performed on the grouped metabolic responders versus non-responders. Results 
are representative of two independent experiments (e) Left: Immunoblot of whole cell lysate 
of HK301 cells overexpressing GFP control or GLUT1 and GLUT3 (GLUT1/3). Right: 
Changes in glucose consumption or lactate secretion of HK301-GFP or HK301-GLUT1/3 
after 12 hours of 1 μM erlotinib treatment. Values are relative to vehicle control (mean ± 
s.d., n ≥ 5). (f) Same as (d) using HK301-GFP or HK301-GLUT1/3 cells (left) or GBM39-
GFP or GBM39-GLUT1/3 cells (right). In the box plots, the central rectangle spans the first 
quartile to the third quartile (the interquartile range or IQR), the central line inside the 
rectangle shows the mean, and whiskers above and below the box show the locations of the 
minimum and maximum within 1.5 IQR of the lower quartile and the upper quartile, 
respectively. Comparisons were made using two-tailed unpaired Student's t-test. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.
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Figure 2. Cytoplasmic p53 links EGFR to intrinsic apoptosis
(a) Immunoblot of indicated proteins in two responders (HK301 and HK336) expressing 
CRISPR/CAS9 protein with control guide RNA (sgCtrl) or p53 guide RNA (p53KO). (b) 
The % change, relative to vehicle control, in apoptotic priming as determined by cytochrome 
c release following dynamic BH3 profiling with BIM peptides in sgCtrl and p53KO cells 
treated with 1 μM erlotinib for 24 hours (mean ± s.d., n = 2). BIM was selected based on 
exhibiting the greatest dynamic range from tested synthetic BH3 peptides (Supplemental 
Fig. 4). Results are representative of two independent experiments. (c) Immunoblot of 
indicated proteins in HK301 sgCtrl, p53KO, p53KO + p53cyto, and p53KO + p53wt. (d) 
Immunofluorescence of p53 protein combined with DAPI staining to reveal protein 
localization in HK301 sgCtrl, p53KO + p53cyto, and p53KO + p53wt (scale bars = 20 μm). 
(e) Changes in indicated mRNA levels following 100 nM doxorubicin treatment for 24 hours 
in HK301 sgCtrl, p53KO, p53KO + p53cyto, and p53KO + p53wt. Levels were normalized to 
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respective DMSO treated cells (mean ± s.d., n = 3). (f) Same as (b) but in HK301 sgCtrl, 
p53KO, p53KO + p53cyto, and p53KO + p53wt (mean ± s.d., n = 2). Results are 
representative of two independent experiments. (g) Same as (e) but in HK301 sgCtrl, 
p53KO, p53KO + p53R175H, p53KO + p53R273H, and p53KO + p53NES (mean ± s.d., n = 3). 
(h) Same as (b) and (f) but in HK301 sgCtrl, p53KO, p53KO + p53R175H, p53KO + 
p53R273H, and p53KO + p53NES (mean ± s.d., n = 2). Results are representative of two 
independent experiments. Comparisons were made using two-tailed unpaired Student's t-
test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 3. Bcl-xL prevents GBM cell death by binding to and sequestering cytoplasmic p53
(a) Immunoprecipitation of p53 in two metabolic responders (HK301 and GBM39) 
following 24 hours of 1 μM erlotinib treatment. Immunoprecipitation was performed with 
immunoglobulin G control antibody or anti-p53 antibody, and the immunoprecipitate was 
probed with the indicated antibodies. Below are respective pre-immunoprecipitation lysates 
(input). (b) Same as (a) but in two non-responders (HK393 and HK254). (c) Same as (a) and 
(b) but in HK301-GFP and HK301-GLUT1/3. (d) HK301 was treated for 24 hours with 1 
μM erlotinib, 1 μM WEHI-539, or both and immunoprecipitation and immunoblotting was 
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performed as described previously. (e) Annexin V staining of two responders (GBM39 and 
HK301) and a non-responder (HK393) following 72 hours of treatment with 1 μM erlotinib, 
5 μM WEHI-539, or both (mean ± s.d., n = 2). (f) Annexin V staining of HK301-GFP and 
HK301-GLUT1/3 following 72 hours of treatment with 1 μM erlotinib, 5 μM wehi-539, or 
both (mean ± s.d., n = 2). All results are representative of two individual experiments. 
Comparisons were made using two-tailed unpaired Student's t-test. *p<0.05, **p<0.01.
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Figure 4. Synthetic lethality with combined targeting of EGFR and p53
(a) Summary of alterations in EGFR and genes involved in p53 regulation across 273 GBM 
samples. (b) Table indicating the significant associations between alterations in EGFR and 
genes involved in the p53 pathway. (c) Annexin V staining of a metabolic responder (left: 
HK301) and non-responder (right: HK393) treated with varying concentrations of erlotinib, 
nutlin, and in combination represented as a 6 × 6 dose-titration matrix. (d) The dose-titration 
of erlotinib and nutlin as described in (c) was conducted across 10 metabolic responders and 
6 non-responders (all p53 wild-type), and the synergy score was calculated (see Materials 
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and Methods) (mean ± s.d., n = 2). Results are representative of two independent 
experiments. (e) Annexin V staining of HK301-GFP and HK301 GLUT1/3 following 72 
hours of treatment with 1 μM erlotinib, 2.5 μM nutlin, or both (mean ± s.d., n = 3). Results 
are representative of two independent experiments. (f) Same as (e) but in HK301-sgCtrl and 
HK301 p53KO (mean ± s.d., n = 3). Results are representative of two independent 
experiments. (g) HK301 was treated for 24 hours with 1 μM erlotinib, 2.5 μM nutlin, or in 
combination. Immunoprecipitation was performed with immunoglobulin G control antibody 
or anti-p53 antibody, and the immunoprecipitate was probed with the indicated antibodies. 
Below are respective pre-immunoprecipitation lysates (input). Comparisons were made 
using two-tailed unpaired Student's t-test. ** p<0.01, *** p<0.001, **** p<0.0001
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Figure 5. Modulation of glucose metabolism primes GBM for p53-mediated cell death
(a) % change in 18F-FDG uptake after 4 hours of 1 μM erlotinib, 1 mM 2DG, or 1 μM 
pictilisib treatment relative to vehicle in HK393 and HK254 (mean ± s.d., n = 3). (b) The % 
change, relative to vehicle control, in apoptotic priming as determined by cytochrome c 
release following dynamic BH3 profiling using BIM peptides in HK393 and HK254 
following 1 μM erlotinib, 1 mM 2DG, or 1 μM pictilisib for 24 hours (mean ± s.d., n = 2). 
Results are representative of two independent experiments (c) Same as (b) but in HK393 
sgCtrl and p53KO (mean ± s.d., n = 2). (d) Immunoprecipitation of p53 in HK393 and 
HK254 following 24 hours of 1 mM 2DG or 1 μM pictilisib treatment. Immunoprecipitation 
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was performed with immunoglobulin G control antibody or anti-p53 antibody, and the 
immunoprecipitate was probed with the indicated antibodies. Below are respective pre-
immunoprecipitation lysates (input). (e) Synergy score of various drugs (erlotinib, 2DG, and 
pictilisib) in combination with nutlin in HK393 and HK254 (mean ± s.d., n = 2). Results are 
representative of two independent experiments. (f) Annexin V staining of HK393 sgCtrl and 
HK393 p53KO following 72 hours of treatment with 0.5 mM 2DG, 1 μM pictilisib, 1 μM 
nutlin, 2DG + nutlin, or pictilisib + nutlin. (mean ± s.d., n = 2). Results are representative of 
two nindependent experiments. Comparisons were made using two-tailed unpaired Student's 
t-test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 6. Combined targeting of EGFR-driven glucose uptake and p53 suppresses tumor growth 
in vivo
(a) Schematic of approach to use 18F-FDG PET to rapidly predict changes in glucose uptake 
with EGFRi and consequently sensitivity to p53 stabilization with Idasanutlin. (b) 
Representative 18F-FDG PET/CT images of GBM39 intracranial xenografts scanned before 
and after 15 hours of 75 mg/kg erlotinib treatment (n = 3 mice). (c) GBM39 intracranial 
xenografts were treated with vehicle (n = 6), 75 mg/kg erlotinib (n = 9), 50 mg/kg 
Idasanutlin (n = 7), or in combination daily (n = 8), and tumor burden was assessed at 
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indicated days using secreted gaussia luciferase (mean ± s.d.) (see Materials and Methods 
for gaussia luciferase measurements). (d) Same as (b) but in HK393 intracranial xenografts. 
(e) Same as (c) but in HK393 intracranial xenografts (mean ± s.d., n = 7 for all groups). (f) 
% survival of (c). (g) % survival of (e). (h) % survival of metabolic responder HK336 
following indicated treatments for 25 days and then released from drug (n = 7 for all 
groups). (i) % survival of non-responder GS025 following indicated treatments for 25 days 
and then released from drug (n = 9 for all groups). Comparisons for (c) and (e) used data sets 
from the last measurements and were made using two-tailed unpaired t-test. Kaplan–Meier 
survival analysis (log-rank) was used for (f) – (i). **p <0.01, ***p<0.001.
Mai et al. Page 33
Nat Med. Author manuscript; available in PMC 2018 April 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
